Rosetta Genomics Ltd. (USA)
(Public, NASDAQ:ROSG) Watch this stockFind more results for
ROSG
Advertisement
Events
Dec 22, 2009
ROSETTA GENOMICS LTD Shareholders Meeting
- 4:00AM EST -
Sep 29, 2009
ROSETTA GENOMICS LTD at Maxim Group Conference
Sep 9, 2009
ROSETTA GENOMICS LTD at Rodman & Renshaw Annual Global Investment Conference
Sep 8, 2009
Q2 2009 ROSETTA GENOMICS LTD Earnings Conference Call -
Sep 8, 2009
Q2 2009 ROSETTA GENOMICS LTD Earnings Release
|
More events from AOL Finance »
|
Key stats and ratios
| Q2 (Jun '09) | 2008 | |
| Net profit margin | -27135.71% | -626.27% |
| Operating margin | -26921.43% | -1027.13% |
| EBITD margin | - | -999.34% |
| Return on average assets | -84.02% | -40.98% |
| Return on average equity | -119.32% | -47.67% |
| Employees | 111 | - |
Address
10 Plaut Street Science Park POB 4059
Rehovot, 76706
Israel
+972-73-2220700 (Phone)
+972-73-2220701 (Fax)
Rehovot, 76706
Israel
+972-73-2220700 (Phone)
+972-73-2220701 (Fax)
Website links
Company website:
https://www.rosettagenomics.com/
https://www.rosettagenomics.com/
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance
Rosetta Genomics Ltd. (USA) discussed on blogs
Ranking 1100+ Micro Cap Stocks by Upside Potential - NASD100.com ...
- Investor's Resources
- NASD100.com - Daily Stock Rankings
- Nov 20, 2009
Rosetta Genomics Ltd. (USA) discussions
View all discussions »Description
Rosetta Genomics Ltd. (Rosetta) develops microRNA-based diagnostic and therapeutic products. The Company is focused on developing and commercializing these products, establishing alliances with biotechnology and pharmaceutical companies. The Company holds a wholly owned subsidiary in the United States, Rosetta Genomics Inc. The principal business activity of the subsidiary is to expand the research, development and the business development of the Company in the United States. On July 22, 2008, the Company acquired Parkway Clinical Laboratories Inc.
Officers and directors
| Yoav Z. Chelouche | Chairman of the Board | |
| Kenneth A. Berlin | President, Chief Executive Officer | |
| Ranit Aharonov Ph.D. | Executive Vice President - R&D, Head - Computational Biology | |
| Ayelet Chajut Ph.D. | Executive Vice President - R&D, Head - Molecular Biology | |
| Limor Zur-Stoller | Vice President - Finance | |
| Dalia Cohen Ph.D. | Chief Scientific Officer | |
| Tami Fishman Jutkowitz | General Counsel | |
| Ronen Tamir | Chief Commercialization Officer | |
| Isaac Bentwich M.D. | Director | |
| Moshe Many M.D., Ph.D. | Director |